For instance, a phase 1/2 trial evaluating ramucirumab (a mAb targeting VEGFR2) in combination with pembrolizumab for recurrent or metastatic HNSCC demonstrated encouraging results. This evidence concerns the gene KDR and head and neck squamous cell carcinoma.